Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND AND AIMS: Vasodilating drugs targeting the endothelium could reduce long-term harms due to cerebral small vessel disease (cSVD) but there are no commonly-accepted methods to measure short-term disease activity or drug response. In the OxHARP clinical trial, we determined the most sensitive physiological markers of treatment response to sildenafil versus placebo on either transcranial ultrasound (TCD) and MRI, and their validity compared to disease severity and other measures of other physiological mechanisms. METHODS: In the OxHARP double-blind, randomised, placebo-controlled crossover trial we measured aortic blood pressure, mean flow velocity (MFV), cerebral pulsatility, cerebrovascular conductance index (CVCi=MFV/aortic mean BP), cerebral perfusion (pcASL-MRI) and cerebrovascular reactivity to inhaled CO2 on transcranial ultrasound (CVR-TCD) and MRI in white (CVR-WM), grey (CVR-GM) and white matter hyperintensities (CVR-WMH). Effects of 3 weeks of sildenafil were compared to placebo. Validity of markers were determined by between-visit repeatability (ICC); associations with CVR-TCD, CVR-WMH and CVR-GM; associations with other markers; the magnitude of response, and sensitivity, to sildenafil. RESULTS: In 69 participants, repeatability was greatest for MFV, pulsatilty, CVCi and CVR-WMH (ICC>0.8), very good for CVR-TCD and GM-perfusion (ICC>0.7), and good for CVR-GM (ICC<0.6). CVR-TCD was associated with CVR on MRI (CVR-WMH: r2=0.12, p=0.02; CVR-GM: r2=0.22, p=0.001), whilst blood flow measures on TCD (MFV, CVCi) were associated with CVR-TCD and perfusion-MRI (all p<0.05). All markers were associated with WMH volume and improved by sildenafil, but CVCi was most sensitive, requiring only 20 patients for a crossover trial at 80% power, compared to 26 for GM-perfusion or 84 for CVR-GM. CONCLUSIONS: Multiple markers were associated with cSVD, but no single marker reflected all physiological drug effects. CVCi and grey matter perfusion on MRI were the most sensitive markers of disease activity and drug response, although CVR indices may be more specific for endothelial dysfunction.

Original publication

DOI

10.1177/17474930251360093

Type

Journal article

Journal

Int J Stroke

Publication Date

10/07/2025

Keywords

Cerebral pulsatility, Cerebrovascular Reactivity, Clinical trial, MRI, Small Vessel Disease, Ultrasound